Cargando…

Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study

BACKGROUND: Deciding on pharmaceutical subsidy is regarded as a challenging issue for healthcare policymakers in Iran in most times. Public preferences, rarely attended in Iran, could be invaluable for including a particular drug in the list of subsidized medications. OBJECTIVES: The current study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Delpasand, Mansoor, Olyaaeemanesh, Alireza, Jaafaripooyan, Ebrahim, Abdollahiasl, Akbar, Davari, Majid, Kazemi Karyani, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278681/
https://www.ncbi.nlm.nih.gov/pubmed/34256875
http://dx.doi.org/10.1186/s40545-021-00345-4
_version_ 1783722310116573184
author Delpasand, Mansoor
Olyaaeemanesh, Alireza
Jaafaripooyan, Ebrahim
Abdollahiasl, Akbar
Davari, Majid
Kazemi Karyani, Ali
author_facet Delpasand, Mansoor
Olyaaeemanesh, Alireza
Jaafaripooyan, Ebrahim
Abdollahiasl, Akbar
Davari, Majid
Kazemi Karyani, Ali
author_sort Delpasand, Mansoor
collection PubMed
description BACKGROUND: Deciding on pharmaceutical subsidy is regarded as a challenging issue for healthcare policymakers in Iran in most times. Public preferences, rarely attended in Iran, could be invaluable for including a particular drug in the list of subsidized medications. OBJECTIVES: The current study aims to elicit the public preferences to develop an evidence-based decision-making framework for entering a drug into the list of subsidies in Iran. METHODS: Discrete Choice Experiment (DCE) was employed to elicit the public preferences. Around 34 attributes were identified based on the systematic review and interview with 51 experts. By holding an expert panel, 7 attributes were finalized, namely: the survival after treatment, quality of life after treatment (QoL), alternative treatment, age group of the target population, cost burden for the government, disease severity, and drug manufacturer country. Next, 1224 households were selected for the survey in the city of Tehran, using random cluster sampling. Data were analyzed using conditional logit model. RESULTS: The survival after treatment (β = 1.245; SE = 0.053) and cost burden for the government (β = − 0.140; SE = 0.050) had the highest and lowest priority, respectively, in the preferences for allocating subsidy to a drug. In developed region, unlike the other two regions, the level of domestic drug production (β =− 0.302; SE = 0.073) was inversely associated with preferences toward allocating subsidy to a drug. In contrast to other districts, those living in district number one (β = 2.053; SE = 0.138) gave the highest value to promoting the QoL after treatment. CONCLUSIONS: It is suggested that policymakers pay more attention to attributes such as effectiveness and alternative treatment when developing an evidence-based framework for entering a drug into the list of subsidies. This study highlighted the public belief in the government’s subsidy for medicines, provided that, this results in an increased survival and QoL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40545-021-00345-4.
format Online
Article
Text
id pubmed-8278681
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82786812021-07-14 Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study Delpasand, Mansoor Olyaaeemanesh, Alireza Jaafaripooyan, Ebrahim Abdollahiasl, Akbar Davari, Majid Kazemi Karyani, Ali J Pharm Policy Pract Research BACKGROUND: Deciding on pharmaceutical subsidy is regarded as a challenging issue for healthcare policymakers in Iran in most times. Public preferences, rarely attended in Iran, could be invaluable for including a particular drug in the list of subsidized medications. OBJECTIVES: The current study aims to elicit the public preferences to develop an evidence-based decision-making framework for entering a drug into the list of subsidies in Iran. METHODS: Discrete Choice Experiment (DCE) was employed to elicit the public preferences. Around 34 attributes were identified based on the systematic review and interview with 51 experts. By holding an expert panel, 7 attributes were finalized, namely: the survival after treatment, quality of life after treatment (QoL), alternative treatment, age group of the target population, cost burden for the government, disease severity, and drug manufacturer country. Next, 1224 households were selected for the survey in the city of Tehran, using random cluster sampling. Data were analyzed using conditional logit model. RESULTS: The survival after treatment (β = 1.245; SE = 0.053) and cost burden for the government (β = − 0.140; SE = 0.050) had the highest and lowest priority, respectively, in the preferences for allocating subsidy to a drug. In developed region, unlike the other two regions, the level of domestic drug production (β =− 0.302; SE = 0.073) was inversely associated with preferences toward allocating subsidy to a drug. In contrast to other districts, those living in district number one (β = 2.053; SE = 0.138) gave the highest value to promoting the QoL after treatment. CONCLUSIONS: It is suggested that policymakers pay more attention to attributes such as effectiveness and alternative treatment when developing an evidence-based framework for entering a drug into the list of subsidies. This study highlighted the public belief in the government’s subsidy for medicines, provided that, this results in an increased survival and QoL. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40545-021-00345-4. BioMed Central 2021-07-13 /pmc/articles/PMC8278681/ /pubmed/34256875 http://dx.doi.org/10.1186/s40545-021-00345-4 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Delpasand, Mansoor
Olyaaeemanesh, Alireza
Jaafaripooyan, Ebrahim
Abdollahiasl, Akbar
Davari, Majid
Kazemi Karyani, Ali
Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study
title Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study
title_full Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study
title_fullStr Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study
title_full_unstemmed Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study
title_short Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study
title_sort eliciting the public preferences for pharmaceutical subsidy in iran: a discrete choice experiment study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278681/
https://www.ncbi.nlm.nih.gov/pubmed/34256875
http://dx.doi.org/10.1186/s40545-021-00345-4
work_keys_str_mv AT delpasandmansoor elicitingthepublicpreferencesforpharmaceuticalsubsidyiniranadiscretechoiceexperimentstudy
AT olyaaeemaneshalireza elicitingthepublicpreferencesforpharmaceuticalsubsidyiniranadiscretechoiceexperimentstudy
AT jaafaripooyanebrahim elicitingthepublicpreferencesforpharmaceuticalsubsidyiniranadiscretechoiceexperimentstudy
AT abdollahiaslakbar elicitingthepublicpreferencesforpharmaceuticalsubsidyiniranadiscretechoiceexperimentstudy
AT davarimajid elicitingthepublicpreferencesforpharmaceuticalsubsidyiniranadiscretechoiceexperimentstudy
AT kazemikaryaniali elicitingthepublicpreferencesforpharmaceuticalsubsidyiniranadiscretechoiceexperimentstudy